March 5, 2024
In Vitro Lung Model Market

Vitro Lung Model Market Propelled by increasing asthma and COPD cases

Global in vitro lung models or otherwise called biologically active lung on chip models are novel 3D tissue engineered platforms that incorporates functional lung tissue architecture coupled with integrated microfluidic circulatory system. These lung models recreate physiological breathing motions and tissue-tissue interactions happening inside the lungs. They mimic key functions of lungs such as gas exchange, mechanical breathing and assess response of lung tissue to drugs, particulate matter and toxins in a realistic but controlled extracorporeal environment. Such models overcome limitations associated with traditional 2D cell cultures and animal testing models.

The global in vitro lung model market is estimated to be valued at US$ 279.8 million in 2024 and is expected to exhibit a CAGR of 14% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.

Market key trends:

The increasing prevalence of chronic respiratory diseases such as asthma and chronic obstructive pulmonary diseases (COPD) globally has raised the need for robust preclinical testing of new drug candidates and toxicological assessment of inhaled substances before human trials. As per insights from World Health Organization, around 235 million people suffer from asthma while over 65 million have COPD worldwide. Traditional animal models do not accurately mimic human lung physiology and pathology. Adoption of novel 3D tissue engineered in vitro lung models fordrug development and toxicity evaluation is expected to gain significant traction going forward. Sophisticated human lung chip models that reproduces mechanics of breathing and histology of alveoli, capillaries network coming together promises to transform respiratory disease research and accelerate clinical translation.

SWOT Analysis

Strength: The global in vitro lung model market offers simplified lung structure with control over the cellular and biochemical milieu which facilitates complex lung biology research and drug toxicity testing.
Weakness: In vitro lung models lack complex organ level interactions and cellular heterogeneity seen in actual human lungs. Precise mimicry of complex lung anatomy and physiology remains a challenge.
Opportunity: Rising research focus on modeling chronic respiratory diseases, personalized medicine, 3D bioprinting of lung tissues and growing cell therapy offer lucrative growth prospects. Also, industry initiatives to develop advanced human lung-on-chip models present opportunities.
Threats: High costs associated with development of complex 3D organoid and microfluidic lung models. Strict regulatory guidelines for testing and commercialization of alternative models could hamper market growth to some extent.

Key Takeaways

The global in vitro lung model market is expected to witness high growth over the forecast period of 2024 to 2031 supported by rising research in respiratory drug development and toxicity screening. The market size was valued at US$279.8 million for 2024 and projected to reach over US$779.5 million by 2031 registering a CAGR of 14%.

Regional analysis: North America presently accounts for the largest share of the global in vitro lung model market led by ongoing research initiatives and funding from organizations like NIH and presence of key market players. Asia Pacific is identified as the fastest growing region with increasing government support for life sciences research.

Key players operating in the in vitro lung model market are Epithelix, MATTEK, Lonza, Emulate, AlveoliX AG, Nortis, CN Bio Innovations Ltd, MIMETAS, InSphero, ATTC Global, Tissuse GmbH and Cn Bio Innovations Limited. These companies are focused on developing advanced 3D human lung-on-chip platforms and industry partnerships for validation and commercialization of innovative preclinical models.

1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it